nafamostat has been researched along with Shock, Septic in 12 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the ideal dosage and efficacy of nafamostat mesilate for use with ECMO in patients with acute cardiac or respiratory failure." | 1.37 | Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. ( Han, SJ; Hong, KS; Kim, HS; Kim, KI; Lee, SH; Lee, WK; Whang, SM, 2011) |
| "Specific treatments in septic shock should be instituted administration of glucocorticoid, antibiotics, protease inhibitor and lipoxygenase inhibitor." | 1.28 | [Effects of anti-toxic agents in septic shock]. ( Asaishi, K; Ebata, T; Hasegawa, I; Hayasaka, H; Hiraike, N; Minamida, H; Yamamoto, Y, 1989) |
| ", Forssman shock, Forssman cutaneous vasculitis, zymosan-induced paw edema, endotoxin shock and local Shwartzman reaction, FUT-175 was highly effective in that, for example, intravenous dosing at 3 mg/kg could completely protect guinea pigs from the lethal Forssman shock." | 1.27 | Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. ( Aoyama, T; Fujita, M; Ino, Y; Koshiyama, Y; Oda, M; Ozeki, M; Sato, T; Suzuki, S, 1984) |
| "Phosphoenolpyruvate (PEP) levels were increased 30% above peritonitis values." | 1.27 | Effect of a new synthetic complement inhibitor on hepatic glycolytic intermediates in septic rats. ( Apantaku, FO; Ebata, T; Kuttner, RE; Schumer, W, 1983) |
| "and 25 mg/kg p." | 1.26 | Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. ( Fujii, S; Hitomi, Y, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (75.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, SJ | 1 |
| Kim, HS | 1 |
| Kim, KI | 1 |
| Whang, SM | 1 |
| Hong, KS | 1 |
| Lee, WK | 1 |
| Lee, SH | 1 |
| Minamiya, Y | 1 |
| Saito, S | 1 |
| Nakamura, M | 1 |
| Tozawa, K | 1 |
| Saito, H | 1 |
| Matsuzaki, I | 1 |
| Ogawa, J | 1 |
| Hitomi, Y | 1 |
| Fujii, S | 1 |
| Miyazaki, M | 1 |
| Yoda, K | 1 |
| Ogli, K | 1 |
| Yokono, S | 1 |
| Aoyama, T | 1 |
| Ino, Y | 2 |
| Ozeki, M | 1 |
| Oda, M | 1 |
| Sato, T | 2 |
| Koshiyama, Y | 2 |
| Suzuki, S | 2 |
| Fujita, M | 1 |
| Ebata, T | 4 |
| Hirata, K | 1 |
| Denno, R | 2 |
| Gotoh, Y | 2 |
| Azuma, K | 2 |
| Ishida, K | 1 |
| Hasegawa, I | 2 |
| Hayasaka, H | 3 |
| Kuttner, RE | 1 |
| Apantaku, FO | 1 |
| Schumer, W | 1 |
| Kobayashi, K | 1 |
| Totsuka, M | 1 |
| Porcel, JM | 1 |
| Asaishi, K | 1 |
| Hiraike, N | 1 |
| Yamamoto, Y | 1 |
| Minamida, H | 1 |
| Okuda, Y | 1 |
| Ogata, H | 1 |
| Suzuki, K | 1 |
| Iwaki, M | 1 |
| Yoshikawa, T | 1 |
| Kondo, M | 1 |
12 other studies available for nafamostat and Shock, Septic
| Article | Year |
|---|---|
Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.
Topics: Acute Disease; Anticoagulants; Benzamidines; Dose-Response Relationship, Drug; Extracorporeal Membra | 2011 |
Nafamostat mesilate attenuates radical formation in the rat lung infused with endotoxin.
Topics: Animals; Benzamidines; Cell Adhesion; Complement C3a; Endotoxins; Free Radicals; Guanidines; Lung; M | 2002 |
Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor.
Topics: Animals; Arthus Reaction; Benzamidines; Complement Inactivator Proteins; Forssman Antigen; Guanidine | 1982 |
[Problems in the use of newly introduced anti-shock agents].
Topics: Adrenal Cortex Hormones; Animals; Benzamidines; Complement Inactivator Proteins; Gabexate; Guanidine | 1983 |
Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.
Topics: Animals; Anti-Inflammatory Agents; Benzamidines; Complement Activation; Complement Inactivator Prote | 1984 |
[Hepatic carbohydrate metabolism in endotoxic shock--effect of a complement inhibitor].
Topics: Animals; Benzamidines; Complement Inactivator Proteins; Fructosediphosphates; Gluconeogenesis; Gluco | 1983 |
Effect of a new synthetic complement inhibitor on hepatic glycolytic intermediates in septic rats.
Topics: Animals; Benzamidines; Complement Inactivator Proteins; Glycolysis; Guanidines; Liver; Male; Periton | 1983 |
[Effects of FUT-175 in endotoxin shock (author's transl)].
Topics: Animals; Benzamidines; Guanidines; Histamine; Male; Mice; Mice, Inbred ICR; Protease Inhibitors; Rab | 1982 |
[Complement inhibition: a new therapeutic modality?].
Topics: Adult; Animals; Antigens, CD; Benzamidines; Blood Proteins; Carrier Proteins; CD55 Antigens; CD59 An | 1995 |
[Effects of anti-toxic agents in septic shock].
Topics: Animals; Benzamidines; Benzoquinones; Dexamethasone; Fibrin Fibrinogen Degradation Products; Guanidi | 1989 |
[The effect of the protease inhibitor FUT-175 on phospholipase A2, complement, prostaglandins and prekallikrein during endotoxin shock].
Topics: Animals; Benzamidines; Complement C3; Dogs; Guanidines; Phospholipases; Phospholipases A; Phospholip | 1989 |
[Effect of FUT-175 on endotoxin-induced shock in the dog].
Topics: Animals; Benzamidines; Dogs; Guanidines; Shock, Septic; Trypsin Inhibitors | 1988 |